Moderna (MRNA) Cash & Current Investments (2017 - 2026)

Moderna (MRNA) has 10 years of Cash & Current Investments data on file, last reported at $5.2 billion in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 12.89% year-over-year to $5.2 billion in Q1 2026; TTM through Mar 2026 was $5.2 billion, a 12.89% decrease from a year earlier, with the FY2025 full-year figure at $5.8 billion, down 17.45% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $5.2 billion, down from $5.8 billion in the prior quarter.
• Over the last five years, Cash & Current Investments for MRNA reached as high as $10.1 billion in Q1 2022 and fell as low as $4.5 billion in Q3 2025.
• Historically, Cash & Current Investments has averaged $7.5 billion across 5 years, with a median of $7.9 billion in 2022.
• Across the five-year window, Cash & Current Investments soared 30.77% in 2022 and tumbled 39.55% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $9.9 billion in 2022, then fell by 13.11% to $8.6 billion in 2023, then declined by 18.35% to $7.0 billion in 2024, then decreased by 17.45% to $5.8 billion in 2025, then slipped by 10.24% to $5.2 billion in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $5.2 billion in Q1 2026, $5.8 billion in Q4 2025, and $4.5 billion in Q3 2025.